An observational study in Tricuspid Regurgitation, Tricuspid Valve Insufficiency and Cardio-Renal Syndrome, sponsored by Robert Bosch Medical Center. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-11.
Sponsored by Robert Bosch Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Tricuspid Valve Insufficiency with a site in Germany — 24 open to participants now, 31 under way, none of them phase 3. Tricuspid Valve Insufficiency · Germany.
Among the 51 studies in Tricuspid Valve Insufficiency with a site in Germany, this one is the 24th largest by planned enrollment of the 26 observational ones that give a count, is one of 3 that started in 2025, is one of 26 observational ones, reaches primary completion later than 13 of the 30 other live ones, and was the 46th registered.
229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.
Browse Tricuspid Valve Insufficiency studies →24 of the 51 studies in Tricuspid Valve Insufficiency with a site in Germany are open now. Recruiting first, the newest first:
Abbott Medical Devices · Sites in Germany, United States, France and 2 more countries
Ages 18+
LMU Klinikum · Sites in Germany
Ages 18+
Cardiovalve Ltd. · Sites in Germany
Ages 18–85
Heart and Diabetes Center North-Rhine Westfalia · Sites in Germany
Ages 18+
Medical University of Vienna · Sites in Germany, Austria, Italy and 1 more country
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 100 is below the median of 225 across 96 observational studies indexed under Tricuspid Valve Insufficiency.
Median enrollment 60 across the 25 interventional studies, 506 across the 26 observational. Of the 14 that completed or were terminated, 5 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 51 have an industry lead sponsor. The 10 most frequent:
Robert Bosch Medical Center is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Robert Bosch Medical Center has 1 study filed under Tricuspid Valve Insufficiency — fewer than ten, so there is no comparison to draw.
6 of the studies in Tricuspid Valve Insufficiency with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05825898Ottawa Heart Institute Research CorporationOutcome of Patients With Severe Functional TR According to Medical, Transcatheter or Surgical Treatment | 2026-12 |
| NCT07464106Robert Bosch Medical CenterEvaluation of the Impact of Interventional Treatments for Symptomatic, Severe Tricuspid Valve Insufficiency on Renal Integrity and Function, as Well as on Physical Function and Activity in Older Adults. | 2026-12 |
| NCT06212193Innoventric LTDInnoventric Trillium™ Stent Graft Early Feasibility Study (EFS) | 2026-12-20 |
| NCT05797519VDyne, Inc.Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation | 2026-12-30 |
| NCT07342036Hazem OmranProspective Study of Lead-associated Tricuspid Regurgitation in Patients Undergoing New Transvalvular Lead Insertion | 2027-01-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 51 studies in Tricuspid Valve Insufficiency with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The hypothesis is that renal function will improve following tricuspid valve intervention. A reduction in renal biomarkers is also expected. Furthermore, based on previous assessments, it is anticipated that there will be an improvement in volume status (reduced edema), symptom burden, and physical capacity in patients. Additionally, the study will assess the impact of the intervention on functional parameters such as motor capacity, physical activity, performance of activities of daily living, and ultimately, participation and quality of life.
The study population includes adult patients with severe symptomatic tricuspid valve insufficiency who are referred for TriClip/TricValve screening and are aged 18 years or older. Participants must be able to provide informed consent and have the capacity to walk short distances with the aid of mobility devices.
Exclusion criteria include dialysis-dependent or terminal kidney disease, inability to comply with study-related assessments (e.g., due to dementia or cognitive decline), severe anemia (Hb \<7 g/dl), and the need for a tricuspid valve intervention with palliative intent, with a likely imminent death. Additionally, patients who are unable or unwilling to provide informed consent will be excluded from the study.
This population represents individuals who are eligible for the intervention, while the exclusions ensure that participants can meaningfully engage in the study assessments and outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tricuspid regurgitation group prior to intervention and after intervention
Procedure: Transcatheter edge-to-edge repair (TEER)
Routine intervention, observational
Change in estimated glomerular filtration rate (eGFR) slope
Annual change in estimated glomerular filtration rate (eGFR) calculated using the CKD-EPI equation based on serial serum creatinine measurements (ml/min/1.73m² per year)
Time frame: Baseline, 6 months, 12 months, and 24 months
Incidence of acute kidney injury (AKI)
Occurrence of acute kidney injury defined according to Kidney Disease: Improving Global Outcomes (KDIGO) criteria based on changes in serum creatinine.
Time frame: Baseline, 6 months, 12 months, and 24 months
Physical activity assessed using the activPAL4 micro activity monitor
Physical activity measured over a 7-day monitoring period using the activPAL4 micro activity monitor (PAL Technologies, Glasgow, UK)
Time frame: Baseline, 6 months, 12 months, and 24 months
Change in functional exercise capacity assessed with the 6-minute walk test (6MWT)
Change in functional exercise capacity measured by the 6-minute walk test (6MWT)
Time frame: Baseline, 6 months, 12 months, and 24 months
Change in kidney venous stasis index (KVSI)
Change in kidney venous stasis index (KVSI) measured by duplex ultrasound
Time frame: Baseline, 6 months, 12 months, and 24 months
Change in body mass index (BMI)
Change in body mass index calculated as body weight in kilograms divided by height in meters squared (kg/m²).
Time frame: Baseline, 6 months, 12 months, and 24 months
Hospitalizations due to heart failure
Number of hospitalizations due to worsening heart failure during the study period.
Time frame: Baseline, 6 months, 12 months, and 24 months
Change in disease-specific quality of life assessed with the Kansas City Cardiomyopathy Questionnaire (KCCQ-12)
Change in disease-specific quality of life measured using the Kansas City Cardiomyopathy Questionnaire short form (KCCQ-12)
Time frame: Baseline, 6 months, 12 months, and 24 months
Change in independence in activities of daily living assessed with the Katz Index
Change in independence in activities of daily living measured using the Katz Index.
Time frame: Baseline, 6 months, 12 months, and 24 months
Change in frailty assessed using the Clinical Frailty Scale (CFS)
Change in frailty status measured using the Clinical Frailty Scale (CFS)
Time frame: Baseline, 6 months, 12 months, and 24 months
Change in hand grip strength measured using a Jamar dynamometer
Change in muscle strength assessed by hand grip strength using a manual dynamometer (Jamar).
Time frame: Baseline, 6 months, 12 months, and 24 months
Change in functional mobility assessed with the Timed Up and Go Test (TUG)
Change in functional mobility measured using the Timed Up and Go Test (TUG), assessing the time required to stand up, walk three meters, turn, return, and sit down.
Time frame: Baseline, 6 months, 12 months, and 24 months
Change in urinary albumin-to-creatinine ratio (UACR)
Change in albuminuria measured as urinary albumin-to-creatinine ratio (UACR) in spot urine samples (mg/gCreatinine)
Time frame: Baseline, 6 months, 12 months, and 24 months
Prevalence of chronic kidney disease (CKD)
Presence of chronic kidney disease defined according to KDIGO criteria based on estimated glomerular filtration rate (eGFR) and markers of kidney damage.
Time frame: Baseline, 6 months, 12 months, and 24 months
Incidence of dialysis initiation
Initiation of chronic renal replacement therapy (hemodialysis or peritoneal dialysis)
Time frame: Baseline, 6 months, 12 months, and 24 months
All-cause mortality
Death from any cause during the study period
Time frame: Baseline, 6 months, 12 months, and 24 months
Change in cognitive function assessed with the Blessed Orientation-Memory-Concentration Test (BOMCT)
Change in cognitive function measured using the Blessed Orientation-Memory-Concentration Test (BOMCT)
Time frame: Baseline, 6 months, 12 months, and 24 months
Change in emotional well-being assessed with the "Allgemeine Depressionsskala" short form (ADS-K)
Change in depressive symptoms assessed using the short version of the general depression scale (ADS-K)
Time frame: Baseline, 6 months, 12 months, and 24 months
Change in body composition measured by bioelectrical impedance analysis (BIA)
Change in body composition assessed by bioelectrical impedance analysis using the AKERN BIA 101 device.
Time frame: Baseline, 6 months, 12 months, and 24 months
Change in Venous Excess Ultrasound (VExUS) Score
Change in VExUS Score (bedside ultrasound-based approach with a more comprehensive assessment of venous congestion) measured by duplex ultrasound
Time frame: Baseline, 6 months, 12 months, and 24 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.
Of 47 observational studies under Tricuspid Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 106. This study's planned 22 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tricuspid Valve Insufficiency →
Robert Bosch Medical Center